Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TG103 in Overweight/Obese Subjects With Type 2 Diabetes
NCT05063253Phase 2Unknown
- Sponsor
- CSPC Baike Biopharmaceutical
- Start
- Oct 2021
- Primary completion
- Mar 2024
- Modality
- Fc-Fusion Proteins
01
Overview
Phase 2, randomised, double-blind trial of GX-G6 in type 2 diabetes mellitus (T2DM) and obesity (4 arms), sponsored by CSPC Baike Biopharmaceutical. Primary endpoint: Changes in glycosylated hemoglobin at 20 weeks. Status: unknown.
02
Drugs
GX-G6
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT05063253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05063253.